Silverback Therapeutics Inc

-0.03 (-0.43%)
Earnings Announcements

Silverback Therapeutics Posts Quarterly Loss Per Share Of $0.65

Published: 11/10/2021 21:56 GMT
Silverback Therapeutics Inc (SBTX) - Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update.
Silverback Therapeutics Inc - Qtrly Net Loss per Share Applicable to Common Stockholders, Basic and Diluted $0.65.
Silverback - Cash, Equivalents, and Investments in Quarter-end Expected to Fund Operating Expenses and Capital Expenditure Requirements Into 2024.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.67

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.75

More details on our Analysts Page.